Omnicell (OMCL)
(Delayed Data from NSDQ)
$29.31 USD
+0.02 (0.07%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $29.55 +0.24 (0.82%) 7:58 PM ET
4-Sell of 5 4
B Value D Growth F Momentum C VGM
Price, Consensus and EPS Surprise
OMCL 29.31 +0.02(0.07%)
Will OMCL be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for OMCL based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for OMCL
Omnicell (OMCL) Expected to Beat Earnings Estimates: Should You Buy?
Omnicell (OMCL) Banks on Product Launches, Global Growth
OMCL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why Omnicell (OMCL) Should be in Your Portfolio Now
Why Is Inspire (INSP) Down 7.3% Since Last Earnings Report?
Omnicell (OMCL) Gains From New Offerings Amid Cost Woes
Other News for OMCL
3 Russell 2000 Stocks to Buy at a 52-week Low in July
Small and Mid-Cap stocks likely to beat/miss this earnings season - BofA
Omnicell to Release Second Quarter 2024 Financial Results on August 1, 2024
Analysts Conflicted on These Healthcare Names: Repare Therapeutics (RPTX), Omnicell (OMCL) and Oscar Health (OSCR)
OMCL Crosses Above Average Analyst Target